<link rel="stylesheet" type="text/css" href="https://ubosquemoodle.unbosque.edu.co/theme/uebtheme/css/stylesUEB.css">
<link rel="stylesheet" type="text/css" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/css/styles.css" />


<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/menu-local.js" type="text/javascript"></script>
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js" type="text/javascript"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js" type="text/javascript"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/timeit.js" type="text/javascript"></script>

<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/dist/css/lightbox.min.css" />

<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/dist/js/lightbox-plus-jquery.min.js" type="text/javascript"></script>


<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>

<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js"></script>

<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js"></script>

<!-- ================== script ================== -->
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>

<!-- ================== lightbox ================== -->




<!-- ================== animate scroll ================== -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/animate.css/3.5.1/animate.min.css">
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/wow/1.1.2/wow.min.js"></script>



<!-- ================== fin animate scroll ================== -->

<!-- ================== css ================== -->
<link rel="stylesheet" type="text/css" href="../css/styles.css">


<!-- ================== contenido ================== -->
<div class="curso-cc mod4" id="pagina5">
	
	<!-- ================== 2º nivel ================== -->
	<div class="container-fluid">
	<div class="row-fluid" id="menu-numero-1">
	</div>
	</div>
	<!-- ================== end 2º nivel ================== -->
	
	<!-- ================== 1º nivel ================== -->
	<div class="container-fluid">
		<div class="row-fluid">
			<div class="span12 banner-cursos" id="banner-mod-4"></div>
		</div>
	</div>
	<!-- ================== end 1º nivel ================== -->
	
	<!-- ================== 3º nivel ================== -->
	<div class="container-fluid">
	<div class="row-fluid">
		<!-- contenido -->
		<div class="span12 content-cc" >
			
			<h2>Capítulo 4 / <span> Bibliografía</span></h2>
			
			<ol>
				<li>Bhoj, V. G., & Sachais, B. S. (2015). Lipoprotein apheresis. Current Atherosclerosis Reports, 17(7), 39. doi:10.1007/s11883-015-0516-7</li>
				<li>Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., . . . Kastelein, J. J. P. (2014). Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials. Journal of the American College of Cardiology, 64(5), 485-494. Retrieved from <a href="https://www.narcis.nl/publication/RecordID/oai:pure.amc.nl:publications%2F8d422aa3-4821-479f-acc5-866519dbad5a" target="_blank">https://www.narcis.nl/publication/RecordID/oai:pure.amc.nl:publications%2F8d422aa3-4821-479f-acc5-866519dbad5a</a></li>
				<li>Bohula, E. A., Morrow, D. A., Giugliano, R. P., Blazing, M. A., He, P., Park, J., . . . Braunwald, E. (2017). Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology, 69(8), 911-921. doi:10.1016/j.jacc.2016.11.070</li>
				<li>Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., . . . Califf, R. M. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine, 372(25), 2387-2397. doi:10.1056/NEJMoa1410489</li>
				<li>Castellano, J. M., Narula, J., Castillo, J., & Fuster, V. (2014). Promoting cardiovascular health worldwide: Strategies, challenges, and opportunities.Revista Espanola De Cardiologia (English Ed.), 67(9), 724-730. doi:10.1016/j.rec.2014.01.023</li>
				<li>Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., . . . Wald, D. (2016). 2016 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 37(39), 2999-3058. doi:10.1093/eurheartj/ehw272</li>
				<li>Collaboration, Cholesterol Treatment Trialists' (CTT). (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. doi:10.1016/S0140-6736(10)61350-5</li>
				<li>Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., . . . Peto, R. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. The Lancet, 388(10059), 2532-2561. Retrieved from <a href="http://researchonline.lshtm.ac.uk/2884467/" target="_blank">http://researchonline.lshtm.ac.uk/2884467/</a></li>
				<li>Descamps, O., Tomassini, J. E., Lin, J., Polis, A. B., Shah, A., Brudi, P., . . . Tershakovec, A. M. (2015). Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis, 240(2), 482-489. doi:10.1016/j.atherosclerosis.2015.03.004</li>
				<li>Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., . . . Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel. European Heart Journal, 38(32), 2459-2472. doi:10.1093/eurheartj/ehx144</li>
				<li>Gidding, S. S., Champagne, M. A., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., . . . Wierzbicki, A. S. (2015). The agenda for familial hypercholesterolemia: A scientific statement from the american heart association. Circulation, 132(22), 2167-2192. doi:10.1161/CIR.0000000000000297</li>
				<li>Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., . . . Davidson, M. (2017). American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 23(Suppl 2), 1-87. doi:10.4158/EP171764.APPGL</li>
				<li>Khera, A. V., Won, H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng, X., . . . Kathiresan, S. (2016). Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. Journal of the American College of Cardiology, 67(22), 2578-2589. doi:10.1016/j.jacc.2016.03.520</li>
				<li>Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J., Borén, J., . . . Catapano, A. L. (2017). 2017 update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. European Heart Journal, doi:10.1093/eurheartj/ehx549</li>
				<li>Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., . . . Smith, S. C. (2016). 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the american college of cardiology task force on clinical expert consensus documents. Journal of the American College of Cardiology, 68(1), 92-125. doi:10.1016/j.jacc.2016.03.519</li>
				<li>Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., . . . Smith, S. C. (2017). 2017 focused update of the 2016 ACC Expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the american college of cardiology task force on expert consensus decision pathways. Journal of the American College of Cardiology, 70(14), 1785-1822. doi:10.1016/j.jacc.2017.07.745</li>
				<li>Merchán, A., Jaramillo, C., Mendoza, F., & Agudelo, J. F. (2011). Se están alcanzando las metas en el perfil lipídico de personas con enfermedad coronaria previa? Revista Colombiana de Cardiología, 18(5), 262-267. doi:10.1016/S0120-5633(11)70196-6 Retrieved from <a href="https://www.sciencedirect.com/science/article/pii/S0120563311701966" target="_blank">https://www.sciencedirect.com/science/article/pii/S0120563311701966</a></li>
				<li>Ministerio de Salud y Proteccion Social, “Analisis de Situation de Salud”, 2015. Available at: <a href="htps://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-2015.pdf" target="_blank">htps://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-2015.pdf</a></li>
				<li>Morales, A. R., Gagnon-Arpin, I., Dobrescu, A., Sutherland, G., Villa, G., Perlaza, J. G., & Habib, M. (2017). Modelling the burden of cardiovascular disease in colombia and the impact of reducing modifiable risk factors. Paper presented at the Ispor 6th Latin American Conference, , 20(9) doi:10.1016/j.jval.2017.08.2852 Retrieved from <a href="https://www.valueinhealthjournal.com/article/S1098-3015(17)33186-8/abstract" target="_blank">https://www.valueinhealthjournal.com/article/S1098-3015(17)33186-8/abstract</a></li>
				<li>Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., . . . Turner, M. B. (2016). Executive summary: Heart disease and stroke statistics--2016 update: A report from the american heart association. Circulation, 133(4), 447-454. doi:10.1161/CIR.0000000000000366</li>
				<li>O'Donnell, M. J., Chin, S. L., Rangarajan, S., Xavier, D., Liu, L., Zhang, H., . . . Yusuf, S. (2016). Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): A case-control study. Lancet (London, England), 388(10046), 761-775. doi:10.1016/S0140-6736(16)30506-2</li>
				<li>Patiño Villada, F. A., Arango Vélez, E. F., Quintero Velásquez, M., & Arenas Sosa, M. M.. (2011). Factores de riesgo cardiovascular en una población urbana de colombia. Revista De Salúd Publica = Journal of Public Health, 13(3), 433. Retrieved from <a href="https://search.proquest.com/docview/1677642190" target="_blank">https://search.proquest.com/docview/1677642190</a></li>
				<li>Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., . . . Pedersen, T. R. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England Journal of Medicine, 376(18), 1713-1722. doi:10.1056/NEJMoa1615664</li>
				<li>Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., . . . Lisheng, L. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet (London, England), 364(9438), 937-952. doi:10.1016/S0140-6736(04)17018-9</li>

			</ol>
			
			<!-- new row inside barra progreso -->
			<div class="row-fluid">
				<div class="span12">
					<h2>Capítulo 4 / <span>Progreso</span> </h2>
				</div>
				<div class="span12" id="progreso100"></div>
			</div>
			<!-- end new row inside -->
			
			<!-- new row inside material modulo -->
			<div class="row-fluid wow  fadeInUp  material-modulo">
				<div id="material-mod-4"></div>
			</div>
			<!-- end new row inside -->
			
			<!-- new row inside botones -->
			<div class="row-fluid">
				<ul class="pager">
				  <li class="previous">
				    <a href="https://ubosquemoodle.unbosque.edu.co/mod/page/view.php?id=252574"><i class="fa fa-caret-left" aria-hidden="true"></i> Anterior</a>
				  </li>
				  <li class="next disabled">
				    <a href="#">Siguiente <i class="fa fa-caret-right" aria-hidden="true"></i></a>
				  </li>
				</ul>
			</div>
			<!-- end new row inside -->
			
		</div>
			
		<!-- end contenido -->
	</div>
	</div>
	<!-- ================== end 3º nivel ================== -->
	
	<!-- ================== 4º nivel ================== -->
	<div class="container-fluid">
		<div class="row-fluid">
			<div class="span" id="footer"></div>
		</div>
	</div>
	<!-- ================== end 4º nivel ================== -->
	
</div>
<!-- ================== contenido ================== -->

<!-- ================== script ================== -->
<script src="../Menu/menu-local.js" type="text/javascript"></script>
<script src="../Menu/timeit.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/menu-local.js" type="text/javascript"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/timeit.js" type="text/javascript"></script>




<!-- ================== fin script ================== -->
<script>
$(".menu-toggle").click(function() {
  $("nav > ul").slideToggle( "700");
  $("nav > ul").css('display','flex');
});

$(document).ready(function(){
    $(window).scrollTop(0);
});
</script>

<script src="jquery.min.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/iframe-code/set-iframe-height-child.js"></script>

<!-- ================== script animate scroll ================== -->
<script>
	new WOW().init();
</script>
<!-- ================== fin script animate scroll ================== -->


<script src="http://code.jquery.com/jquery.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/2.3.2/js/bootstrap.min.js"></script>